COMPASS Pathways Acquires Novel Psychedelics and Prodrugs IP Portfolio
Earlier this week, COMPASS Pathways announced that it has acquired an IP portfolio that seeks to cover a “variety of psychedelic and empathogenic substances, some of which are prodrugs.”
The company says that the IP was developed with Matthias Grill PhD, via his company MiHKAL (presumably meaning Molecules I Have Known and Loved, in a nod to Shulgin’s seminal publications), which is based in Basel, Switzerland: a short distance from the University of Basel where MindMed collaborator Dr. Matthias Liechti’s lab is located.
It’s important to note that, according to the press release, the portfolio contains patent applications, as opposed to allowed or granted patents.
This news comes just a week after CaaMTech announced a $22m Series A financing. The U.S. company is also seeking to generate a robust patent portfolio covering new tryptamines and formulations of psychedelics.
Wesana Commits $1.5m to Exploring Viability of MAPS’ MDMA-Assisted Therapy to Treat Traumatic Brain Injury
Chicago-based Wesana Health has announced that it’s committing to fund an initial $1.5m to assess the viability of using MAPS’ MDMA-assisted therapy protocol to treat traumatic brain injury (TBI). It appears the funds will primarily be used to scope the size of the TBI market, and generate a partnership agreement for a potential joint venture between Wesana and MAPS Public Benefit Corp (PBC).
It is not clear why the pair believe that MDMA-assisted therapy may be effective in the treatment of TBI, but MAPS Exec. Director Rick Doblin said the following:
“Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Consistent with our mission, we seek to investigate treatments for affected patients who can be helped by MDMA – this is an important step in that direction.”
There does appear to be some evidence, in animal studies, that the administration of MDMA one hour prior to a minimal traumatic brain injury (mTBI) can have neuroprotective properties (see Edut et al., 2011 and Edut et al., 2014). But, dosing NHL players, for example, an hour prior to their appearance on the ice is neither practical, nor the suggestion of either party in this proposed collaboration. Rather, Wesana and MAPS will seek to understand whether MDMA-assisted therapy can help treat extant TBI.
The underlying thesis may be related to MDMA’s apparent ability to induce neuroplasticity (see Ly et al., 2018), which is understood to be at least part of “the basis of recovery” for the CNS following injury. It may also be related to the modulation of neuroinflammation that has been observed with other psychedelics, such as DMT.
Prior to this announcement, Wesana’s focus had (at least publicly) been on a psilocybin-based regimen, and on the acquisition of a network of mental health clinics that offered ketamine therapy among other services.
This announcement can also be situated among a broader shift toward an increasing interest in psychedelics as potential therapeutics for brain injuries and neurodegenerative diseases, as covered in a new publication by Kozlowska et al..
Read more on our News page.